Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

被引：5
|
作者：
Lim, Jonathan [1 ]
Samuelsen, Carl [2 ]
Golembesky, Amanda [2 ]
Shrestha, Sulena [3 ]
Wang, Li [3 ]
Griebsch, Ingolf [2 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] STATinMED Res, Plano, TX 75024 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 13期
关键词：
afatinib; EGFR tyrosine kinase inhibitors; erlotinib; first-line treatment; non-small-cell lung cancer; KINASE INHIBITOR-AFATINIB; HEALTH-CARE UTILIZATION; OPEN-LABEL; PHASE-III; REAL-WORLD; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE; TREATMENT PATTERNS; CHANNELING BIAS; GEFITINIB;
D O I：
10.2217/fon-2019-0052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Evaluate duration of therapy among patients treated with afatinib or erlotinib as first-line therapy for non-small-cell lung cancer (NSCLC). Materials & methods: NSCLC patients initiating afatinib or erlotinib between 2014 and 2017 were identified in three large claims databases in the USA. Propensity score matching was conducted to compare the duration of treatment between patients by treatment. Results: Patients prescribed afatinib had a significantly longer median duration of treatment compared with those prescribed erlotinib (12.1 vs 9.9 months; p = 0.035) and experienced a 14% reduction in risk of discontinuing therapy (adjusted hazard ratio: 0.86; CI: 0.75-0.99). Conclusion: First-line treatment duration in a real-world setting was significantly longer for patients prescribed afatinib compared with erlotinib.
引用
收藏
页码：1493 / 1504
页数：12
相关论文
共 50 条
  • [1] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [2] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    Park, Keunchil
    Bennouna, Jaafar
    Boyer, Michael
    Hida, Toyoaki
    Hirsh, Vera
    Kato, Terufumi
    Lug, Shun
    Mok, Tony
    Nakagawa, Kazuhiko
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Schuler, Martin
    Sibilotru, Denis Moro
    Tan, Eng-Huat
    Tanaka, Hiroshi
    We, Yi-Long
    Yang, James C-H
    Zhang, Li
    Zhou, Caicun
    Maerten, Angela
    Tang, Wenbo
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 132 : 126 - 131
  • [3] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [4] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [5] Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
    Koehler, Jens
    Schuler, Martin
    ONKOLOGIE, 2013, 36 (09): : 510 - 518
  • [6] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Kim, Yong-Jin
    Oremus, Mark
    Chen, Helen H.
    McFarlane, Thomas
    Fearon, Danielle
    Horton, Susan
    PHARMACOECONOMICS, 2021, 39 (05) : 537 - 548
  • [7] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Yong-Jin Kim
    Mark Oremus
    Helen H. Chen
    Thomas McFarlane
    Danielle Fearon
    Susan Horton
    PharmacoEconomics, 2021, 39 : 537 - 548
  • [8] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [9] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
    Dillon, Bernice
    Naidoo, Bhash
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (08): : 764 - 765
  • [10] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
12345